Loading insider details...
Beta
Latest Form 4 (Jun 8, 2026): Grant/Award of 75,000 PRME shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | Prime Medicine, Inc. (PRME) | Grant/Award | 75,000 | n/a |
| Jun 5, 2026 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 6,408 | n/a |
| Jan 6, 2026 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/Award | 155 | n/a |
| Aug 6, 2025 | Prime Medicine, Inc. (PRME) | Disposition to Issuer | 39,062 | n/a |
| Jun 5, 2025 | Prime Medicine, Inc. (PRME) | Grant/Award | 55,000 | n/a |
| Jun 5, 2025 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 6,037 | n/a |
| Jan 6, 2025 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/Award | 166 | n/a |
| Nov 13, 2024 | Denali Therapeutics Inc. (DNLI) | Exercise/Conversion | 47,165 | $849.0K |
| Jun 24, 2024 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/Award | 2,120 | n/a |
| Jun 17, 2024 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Exercise/Conversion | 3,388 | n/a |